Clinical Trial Update: Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial assessing effectiveness and safety of SAR156597 for diffuse systemic sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• SAR156597

Snippet

Sponsor: Sanofi | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2022-02-02